Last reviewed · How we verify
carboplatin, thiotepa, and cyclophosphamide
Carboplatin, thiotepa, and cyclophosphamide work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells.
Carboplatin, thiotepa, and cyclophosphamide work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells. Used for Ovarian cancer, Breast cancer, Lung cancer.
At a glance
| Generic name | carboplatin, thiotepa, and cyclophosphamide |
|---|---|
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that forms platinum-DNA adducts, causing DNA damage and apoptosis. Thiotepa is a nitrogen mustard alkylating agent that cross-links DNA, also leading to cell death. Cyclophosphamide is an alkylating agent that forms DNA cross-links and interstrand cross-links, causing DNA damage and cell death.
Approved indications
- Ovarian cancer
- Breast cancer
- Lung cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Fatigue
- Infection
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors (PHASE4)
- Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (PHASE3)
- Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: